NeuroOne Medical Technologies Corporation — Form 10-Q
Reporting period: Three months ended December 31, 2023 (fiscal first quarter); filed February 13, 2024. Financial statements are unaudited. NeuroOne develops and commercializes neurological medical devices, including cortical and sEEG electrodes and an RF ablation system.
Financial performance and position
| Metric | Q1 FY2024 | Q1 FY2023 |
|---|---|---|
| Product revenue | $977,649 | $114,579 |
| Collaboration revenue | $0 | $1,455,188 |
| Product gross profit (loss) | $266,314; 27.2% gross margin | $(12,307) |
| Operating expenses | $3,656,789 | $3,227,233 |
| Operating loss | $(3,390,475) | $(1,784,352) |
| Net loss | $(3,344,900), or $(0.14) per share | $(1,732,769), or $(0.11) per share |
| Cash used in operating activities | $(3,809,391) | $(3,492,253) |
- Cash and cash equivalents were $2.68 million at December 31, 2023, down from $5.32 million at September 30, 2023. Total assets were $5.82 million and stockholders’ equity was $4.42 million.
- Current liabilities were $1.38 million. Total liabilities were $1.40 million, including operating lease liabilities; the filing reports no borrowing balance in the presented balance sheet.
- Financing activities provided $1.21 million, primarily from ATM share sales. Cash declined by $2.64 million during the quarter.
- Accounts receivable was $543,399, compared with none reported at September 30, 2023. Inventory was $1.61 million.
Material changes versus the prior period
- Product revenue grew by $863,070, while collaboration revenue fell by $1.46 million to zero. The prior-year collaboration revenue related to completion of a Zimmer sEEG exclusivity-maintenance obligation, not recurring quarterly revenue.
- Product gross profit improved by $278,621, reaching a 27.2% margin. Product cost of revenue rose to $711,335 alongside higher sales.
- SG&A increased $509,735 to $2.17 million, mainly due to payroll, legal, and public-company costs. R&D decreased $80,179 to $1.48 million.
- Net loss increased $1.61 million year over year. Operating cash use rose by approximately $317,000.
- The weighted-average share count increased to 24.0 million from 16.2 million. The company issued 868,243 shares through its ATM during the quarter.
Outlook, risks, and unusual items
- Going concern and financing: NeuroOne reported an accumulated deficit of $66.0 million and stated that substantial doubt exists about its ability to continue as a going concern. The filing says liquidity is adequate through mid-2024, but also says existing cash may not fund operations for at least 12 months from the filing date. Additional financing is needed; reduced spending or cessation of operations may be necessary if funding or expected results do not materialize.
- Subsequent financing: On January 5, 2024, the company increased the ATM program’s aggregate offering capacity to $9.3 million, including shares previously sold. In January it sold another 1,080,314 shares for net proceeds of $1.5 million.
- Commercial and regulatory developments: FDA 510(k) clearance for the OneRF ablation system was received in December 2023; commercial launch was expected in the second calendar quarter of 2024. The company had launched its sEEG product line in 2023 and was ramping production. No formal financial guidance was provided.
- Commercial dependence: One customer accounted for all product and collaboration revenue. Zimmer has exclusive distribution rights for the company’s covered electrode products; delays or failure to commercialize could materially harm results. A single contract manufacturer produces Strip/Grid and sEEG products.
- Other risks and commitments: The company expects operating costs to increase as it develops and commercializes products. Risks include access to capital, product adoption, reimbursement, regulatory and clinical outcomes, manufacturing performance, intellectual property, and macroeconomic and supply-chain conditions. WARF royalties include a $150,000 annual minimum while the license remains in effect. The filing reports no current legal proceeding management considers likely to have a material adverse effect and no recorded loss contingency.
- Share-based compensation and dilution: The company granted 1,160,669 stock options in the quarter. A further 1,051,556 shares were added to the 2017 equity plan effective January 1, 2024 under its evergreen provision.
Investor verification priorities
- Verify the cash runway, near-term cash burn, and whether additional financing is available on acceptable terms, including the effect of post-quarter ATM sales.
- Track product revenue, gross margin, receivable collection, and the extent to which sales depend on Zimmer and its commercialization efforts.
- Confirm timing and progress of the OneRF launch, sEEG sales ramp, and any related regulatory or clinical developments.
- Assess potential dilution from ATM issuance, outstanding warrants and options, and equity-plan share increases.
- Monitor manufacturing concentration, inventory levels, royalty obligations, and any changes to the company’s going-concern assessment.